One Federal St.//Boston, MA 02110-1726//United States
Mark B. Stein provides comprehensive legal services to private equity and venture capital funds, with a substantial number of transactions in the healthcare, life sciences, technology, and financial services technology space. He focuses on mergers and acquisitions (M&A), private equity, and venture capital transactions, as well as the general corporate representation of a variety of operating companies. Mark, who is recommended by The Legal 500, is a frequent speaker on emerging company topics. Mark co-leads the healthcare industry initiative.
His background includes counseling institutional investors on portfolio investment and buy-out transactions and investments in private equity funds, as well as carve-outs, divestitures and asset acquisitions. Mark serves as outside general counsel to companies across a range of industries, including information technology, software, life sciences, healthcare, financial services technology, consumer products, and e-commerce. Clients also turn to him for assistance with a variety of commercial matters, from distribution and licensing agreements to joint ventures and financial transactions.
Active on the boards of several nonprofits, Mark currently serves on the board of directors of Jewish Vocational Services of Boston. He advises the Dartmouth Entrepreneurial Network and the Barris Incubator at the Tuck School of Business at Dartmouth.
Before entering private practice, Mark worked in government service. He held the positions of deputy executive director and acting executive director of the Massachusetts Office of International Trade and Investment. He also served as legislative assistant to a US senator from New Hampshire and worked as a Foreign Service officer with the US Department of State, where he served in the Bureau of Near Eastern and South Asian Affairs and at the US Embassy in Ankara, Turkey.
Mark is proficient in Turkish, French, and Russian.
selected representations
CRA Health, LLC, a breast cancer risk assessment company spinoff from Massachusetts General Hospital, in its sale valued up to $22 million, to Volpra Health. Buyer is Volpara Health Technologies Limited. We represented the selling stockholders of CRA. Stock deal. Cash consideration. Only deal attribute was an earn-out. Base price was $18 million, $4 million earn-out.
AcadiaSoft Inc. in its acquisition of Quaternion (Ireland), a capital markets consulting and software company. Stock deal, Cash consideration. We represented Acadiasoft as Buyer. Only deal attribute was earn-out. $7.5 million base purchase price plus $12.5 million earn-out.
CarGurus in its acquisition of PistonHeads, a UK automotive website
Artemis Capital Partners in its acquisition of Superior Technical Ceramics, an innovator in advanced ceramic technologies
AcadiaSoft, a provider of margin automation solutions for counterparties engaged in collateral management in the worldwide derivatives industry, in its sale of minority interest to London Stock Exchange
Schweiger Dermatology Group, a dermatology and cosmetic surgery practice, in its $100 million investment by LNK Partners
Vets First Choice, a provider of technology-enabled health care services with a sole focus on animal health, in its merger with the Animal Health division of Henry Schein to form Covetrus
Bullhorn in its acquisition of Talent Rover, recruitment software built on the Salesforce platform
Bullhorn in its acquisition of Jobscience, a provider of recruitment software built on the Salesforce platform
Maestro Health, an employee health and benefits solution provider, in its sale to AXA Group
Awards and Affiliations
Highly Regarded – State, IFLR1000 Financial and Corporate (2021)
Recommended, Media, technology and telecoms: Fintech, The Legal 500 US (2020)
Recommended, M&A/corporate and commercial: Private equity buyouts, The Legal 500 US (2019)
Named, Modern Healthcare’s “Largest Healthcare Firm” (2016–2020)
Chairman, Jewish Vocational Services (Boston)
Ranked, Chambers USA: America's Leading Lawyers for Business (2010–2011, 2014–2015)
Recommended, The Legal 500 (2009–2014)
Life Sciences Star, Financial and Corporate, LMG Life Sciences, (2013–2020)
